Rivaroxaban 15 Mg Shanur And Rivaroxaban 20 Mg Shanur 15 mg/20 mg FC tablets
PDF Leaflet Revision Date: 28 February 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention and treatment of thromboembolic events.
Dosage (summary)
SPAF: 20 mg once daily; DVT/PE: 15 mg twice daily for 3 weeks, then 20 mg once daily.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors (e.g., ketoconazole, ritonavir)
- Other anticoagulants
Contraindications
- Active bleeding
- Severe hepatic disease
- Hypersensitivity to rivaroxaban
Common side effects
- Bleeding
- Anaemia
- Dizziness
Counselling Points
- Take with food
- Report any signs of bleeding
- Do not double dose if missed
Serious warnings
- Increased bleeding risk
- Monitor for signs of bleeding
Important Disclaimer
The Rivaroxaban 15 Mg Shanur And Rivaroxaban 20 Mg Shanur 15 mg/20 mg FC tablets professional information leaflet below is the property of Shanur Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
